Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | GPBAR1 | Q8TDU6 | 7/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL899822 | 0.84 | ALDH1A1 (0.58) | HSD17B10GPBAR1LMNAL3MBTL1MAPT | |
| SCHEMBL899442 | 0.81 | MAPT (0.55) | HSD17B10GPBAR1LMNACYP2C19MAPT | |
| SCHEMBL13734244 | 0.81 | HSD17B10 (0.59) | HSD17B10GPBAR1LMNAL3MBTL1CYP2C19 | |
| SCHEMBL28806449 | 0.80 | NR1H4 (0.55) | HSD17B10GPBAR1LMNAL3MBTL1CYP2C19 | |
| SCHEMBL12694218 | 0.79 | EPAS1 (0.60) | LMNAHTTEPAS1KMT2AALDH1A1 | |
| SCHEMBL459354 | 0.78 | HSD17B10 (0.76) | HSD17B10GPBAR1LMNAL3MBTL1CYP2C19 | |
| SCHEMBL30395456 | 0.78 | HSD17B10 (0.76) | HSD17B10GPBAR1LMNAL3MBTL1CYP2C19 | |
| Hydrochloric Acid SCHEMBL11554371 | 0.77 | HSD17B10 (0.74) | HSD17B10GPBAR1LMNAL3MBTL1CYP2C19 | |
| SCHEMBL12691869 | 0.77 | EPAS1 (0.58) | GPBAR1LMNAHTTEPAS1KMT2A | |
| SCHEMBL28806448 | 0.76 | GPBAR1 (0.47) | HSD17B10GPBAR1CYP2C19MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621920-A1 | NOVEL PIPERAZINE ANALOGS WITH SUBSTITUTED HETEROARYL GROUPS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | Bristol-Myers Squibb Company (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20120245176-A1 | NOVEL PIPERAZINE ANALOGS WITH SUBSTITUTED HETEROARYL GROUPS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-27 | — | — | US | disclosed |
| US-20120245176-A1 | NOVEL PIPERAZINE ANALOGS WITH SUBSTITUTED HETEROARYL GROUPS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-27 | — | — | US | disclosed |
| US-20120245176-A1 | NOVEL PIPERAZINE ANALOGS WITH SUBSTITUTED HETEROARYL GROUPS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-27 | — | — | US | disclosed |
| WO-2012044531-A1 | NOVEL PIPERAZINE ANALOGS WITH SUBSTITUTED HETEROARYL GROUPS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245176-A1 | NOVEL PIPERAZINE ANALOGS WITH SUBSTITUTED HETEROARYL GROUPS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | ZC3HAV1, ZC3HAV1L, BAZ2A | HSD17B10 2876/4885GPBAR1 2916/4885LMNA 2527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.